

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM42/1014

RONALD B. GOLDSTEIN ESQ. PHARMACOPELA, INC. CN 5350 PRINCETON NJ 08543-5340

91

APPLIC	CATION NO.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT		DATE MAILED
0:	3/986,545	12/08/97	003	KEATING J, O	1613	10/14/98
First Named Applicant	DOLLE,		35 U	SC 154(b) term ext. =	0 Days	4

TITLE OF INVENTION HYDROXY-AMINO ACID AMIDES

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	AF	PLN TYPE	SMALL ENTITY	FEE DUE	DATE DUE
1 PH1015DB	544-35	58.000 I	<40	UTILIT	Y YES	\$660.00	01/14/99

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

HOW TO RESPOND TO THIS NOTICE:

- Review the SMALL ENTITY status shown above.
 If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.
- If the SMALL ENTITY is shown as NO:
- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PATENT AND TRADEMARK OFFICE COPY



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NA	MED INVENTOR	ATTORNEY DOCKET NO.		
08/986,545	12/08/97	DOLLE		R	PH1015DB	
- HM42/1014			4 7	EXAMINER		
RONALD B. GOLDSTEIN ESQ. PHARMACOPELA, INC.				KEATING J,O		
CN 5350	Ma LINE.			ART UNIT	PAPER NUMBER	
PRINCETON N	J 08543-5341)		1613	PI/A	
				DATE MAILED): 10/14/98	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 08/986,545

Applicant(s)

Dolle III et al.

Notice of Allowability

Examiner

Dominic Keating

Group Art Unit 1613



All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
∑ This communication is responsive to <u>applicant's amendment of 7/23/98</u>
∑ The allowed claim(s) is/are 1, 3 and 9, renumbered 1-3, respectively
The drawings filed on are acceptable.
☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
□ All □ Some* □ None of the CERTIFIED copies of the priority documents have been
received.
received in Application No. (Series Code/Serial Number)
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
□ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informal.
including changes required by the Notice of Draftsperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
☐ including changes required by the attached Examiner's Amendment/Comment.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal lettter addressed to the Official Draftsperson.
☐ Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included.
Attachment(s)
□ Notice of References Cited, PTO-892 □ Information Disclosure Statement(s), PTO-1449, Paper No(s).
□ Notice of Draftsperson's Patent Drawing Review, PTO-948 SUPERVISORY FATENT EXAMINER
CROUP 1200
☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material

Application/Control Number: 08/986,545

Art Unit: 1613

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ron Goldstein on Oct. 8, 1998.

The application has been amended as follows:

Claims 2 and 7 have been canceled.

In claim 3, line 1, "2" has been deleted and has been replaced by "1".

In claim 9, line 1, "7" has been deleted and has been replaced by "1".

REASONS FOR ALLOWANCE

2. The following is an examiner's statement of reasons for allowance. In the applicants' amendment of July 23, 1998, the applicants have limited the scope of the Y variable which has eliminated the overlap of the claims with the claims of U.S. Pat. No. 5,734,054 and which has obviated a double patenting rejection. The rejection under 35 U.S.C. 102(e) is withdrawn because the present application and U.S. Pat. No. 5,734,054 share Pharmacopeia, Inc. as a common assignee

Art Unit: 1613

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Telephone Inquiry Contacts

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dominic Keating whose telephone number is (703) 308-4548. The examiner can normally be reached on Monday through Friday from 9 a.m. to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter, can be reached on (703) 308-4532. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Johann Richter

Supervisory Primary Examiner

Art Unit 1613

Technology Center 1

DJK

October 13, 1998